by Eclosion Team | Jun 26, 2019 | Uncategorized
Research supports neurobiological rationale for evidence of neuroprotection obtained in completed Phase 2b clinical trials Protective effects on axonal degeneration and remyelination support potential role of temelimab in treating progressive MS Geneva, Switzerland,...
by Eclosion Team | Jun 24, 2019 | Uncategorized
Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metrics important to PBC patients, including fatigue...
by Eclosion Team | May 7, 2019 | Uncategorized
Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further development in early-onset pediatric population Geneva,...
by Eclosion Team | May 7, 2019 | Uncategorized
Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further development in early-onset pediatric population Geneva,...
by Eclosion Team | May 2, 2019 | Uncategorized
Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial • 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibrotic mechanism • Statistically significant...